Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Research analysts at Zacks Research upped their FY2024 earnings per share estimates for Bristol-Myers Squibb in a research ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

On Thursday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.5 which represents a slight increase of $0.09 or 0.15% from the prior close of $58.41. The stock opened at ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Shareholder Yield Investor model based on the ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.